Swiatkowski M, Pulkowski G, Kłopocka M, Budzyński J, Wiśniewsk E, Kotschy M
Katedra i Klinika Gastroenterologii i Chorób Wewnetrznych Akademii Medycznej im. L. Rydygiera w Bydgoszczy.
Przegl Lek. 2001;58(2):67-70.
Serine protease inhibitors (serpins) are the important factors regulating hemostasis and inflammatory mediators activity. The aim of this study was to determine relationships between plasma serine protease inhibitors activities and the course of ulcerative colitis (uc).
42 patients with uc, 21 in active and 21 in inactive disease phase, and 26 healthy persons (control group) were studied. In all investigated persons activities of alpha 1-proteinase inhibitor (alpha 1-PI), alpha 2-macroglobulin (alpha 2-M), alpha 2-antiplasmin (alpha 2-AP), antithrombin III (ATIII) and plasminogen activator inhibitor type 1 (PAI-1) were determined.
Patients with uc had higher level of alpha 1-PI than control group. In patients with active uc lower alpha 2-M activity was found than in patients with us remission. Alpha 2-M activity below 100% had 58% sensitivity and 71% specificity, and predictive value (odds ratio = 6.25) for histologic appearance of active uc. The correlation between alpha 2-M value and uc activity and time of symptoms duration before the study start was found. Patients with inflammatory process beyond sigmoid had lower alpha 2-AP activity than patients with less extended inflammatory process.
Inflammatory process in large bowel changed the level of plasma serine protease inhibitors activities, what was a result of acute phase reaction (alpha 1-PI) and inhibitors consumption in inflammatory processes (alpha 2-M, alpha 2-AP).
丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制因子)是调节止血和炎症介质活性的重要因素。本研究的目的是确定血浆丝氨酸蛋白酶抑制剂活性与溃疡性结肠炎(UC)病程之间的关系。
研究了42例UC患者,其中21例处于疾病活动期,21例处于非活动期,以及26名健康人(对照组)。测定了所有受调查者的α1-蛋白酶抑制剂(α1-PI)、α2-巨球蛋白(α2-M)、α2-抗纤溶酶(α2-AP)、抗凝血酶III(ATIII)和纤溶酶原激活物抑制剂1型(PAI-1)的活性。
UC患者的α1-PI水平高于对照组。活动期UC患者的α2-M活性低于缓解期患者。α2-M活性低于100%对活动期UC的组织学表现具有58%的敏感性和71%的特异性,以及预测价值(优势比=6.25)。发现α2-M值与UC活动度以及研究开始前症状持续时间之间存在相关性。乙状结肠以外有炎症过程的患者的α2-AP活性低于炎症过程较轻的患者。
大肠的炎症过程改变了血浆丝氨酸蛋白酶抑制剂的活性水平,这是急性期反应(α1-PI)和炎症过程中抑制剂消耗(α2-M、α2-AP)的结果。